Anuncio • May 15
Vicarious Surgical Inc Demonstrates Sustained System Performance And Complex Hernia Procedure Workflows In Pre-Clinical Setting Vicarious Surgical Inc. announced the successful completion of a full-day synthetic abdominal model lab demonstrating sustained system performance and continued procedural workflow progression for the Vicarious Surgical System. During the lab, the Vicarious Surgical System operated fully draped for multiple hours while the CMO, an experienced abdominal surgeon, performed back-to-back IPOM+ and robotic transabdominal preperitoneal (rTAPP) ventral hernia repair workflows. The lab was conducted using the Company’s integrated instrument suite, including needle drivers, graspers, monopolar scissors and electrosurgical energy. The lab represents an important progression beyond the Company’s previously announced integrated benchtop testing milestone by extending validation of the Vicarious Surgical System into sustained procedural workflows under clinically relevant operating conditions. The testing demonstrated continued progress in runtime stability, visualization, instrument control and workflow execution as the Company advances toward design freeze and future cadaveric and in-vivo studies. The Company intends to continue expanding procedural workflow testing and system validation activities as it advances development of the Vicarious Surgical System for ventral hernia repair and other abdominal procedures. Anuncio • Apr 01
Vicarious Surgical Inc. Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair Vicarious Surgical Inc. announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company’s targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar scissors, each of which is designed for use with the Vicarious Surgical System. The successful testing of all three instruments in a unified evaluation serves as a critical step in systematically de-risking the Company's path toward first-in-human use. Notably, the monopolar scissors, which previously demonstrated successful electrical performance in a December porcine lab study, exhibited strong motion and mechanical cutting capabilities following the Company's standard automated calibration and bring-up process. Importantly, instrument and camera sensors remained stable, with no degradation in video or motion quality in the presence of monopolar electrosurgical energy, confirming robust system performance under clinically relevant operating conditions. The successful completion of this benchtop testing positions the Company to advance to the next phase of preclinical validation, including planned cadaveric and porcine studies, as it continues to prepare for first clinical use of the Vicarious Surgical System and execute against a defined series of development milestones leading to design freeze. Anuncio • Mar 05
Vicarious Surgical Inc. Receives Delisting Notice From NYSE On March 3, 2026, the New York Stock Exchange (the NYSE) notified Vicarious Surgical Inc. (the Company) that the NYSE had determined to (A) immediately suspend trading in the Company's common stock, par value $0.0001 per share (the Common Stock), due to a determination that the Company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000 pursuant to Section 802.01B of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Common Stock. The NYSE has stated that it will apply to the Securities and Exchange Commission to delist the Common Stock by filing a Form 25 upon completion of all applicable procedures, including any appeal by the Company of the NYSE's delisting determination, which appeal must be made within ten business days from receipt of the determination. The Company is currently evaluating whether to appeal the delisting determination. The Company has received approval of its application to have the Common Stock quoted on the OTCID market tier (OTCID) operated by the OTC Markets Group Inc. (OTC Markets). The Company expects that the Common Stock will commence quotation on the OTCID at the open of business on March 4, 2026 under the current trading symbol of RBOT. The OTCID is a significantly more limited market than the NYSE, and quotation on any OTC market will result in a less liquid market for existing and potential holders of the Common Stock to trade the Common Stock and could further depress the trading price of the Common Stock. The Company can provide no assurance that the Common Stock will continue to trade on this market, whether broker-dealers will provide and continue to provide public quotes of the Common Stock on this market, or whether the trading volume of the Common Stock will be sufficient to provide for an efficient trading market. The suspension and/or delisting of the Company's common stock from the NYSE could negatively impact the Company by (i) reducing the liquidity and market price of the Common Stock; (ii) reducing the number of investors willing to hold or acquire the Common Stock, which could negatively impact the Company's ability to raise equity financing; (iii) impacting the Company's ability to use a registration statement to offer and sell freely tradable securities, thereby preventing the Company from accessing the public capital markets; and (iv) impairing the Company's ability to provide equity incentives to its employees. New Risk • Feb 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (US$13.1m market cap). Anuncio • Jan 13
Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab Vicarious Surgical announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed key elements of a ventral hernia repair using Vicarious Surgical's pre-DV system as part of a limited-scope feasibility assessment. In parallel, the company executed a series of targeted technical evaluations designed to assess system performance against key engineering and functional specifications. Data generated during the lab, along with structured surgeon feedback, are being incorporated into ongoing design refinement, verification planning, and system optimization efforts. The December in-vivo lab builds on Vicarious Surgical's disciplined, specification-driven development approach and reflects the company's focus on minimizing technical risk through iterative testing, surgeon engagement, and data-driven execution at this stage of system integration. This marks the Company's first in-vivo animal lab conducted in several years, and the first performed with an integrated system architecture rather than early-stage prototypes, providing critical insight into system behavior under realistic surgical conditions. The lab was conducted for research and development purposes only and was not designed to support regulatory submissions or clinical claims. New Risk • Dec 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$51m net loss in 2 years). Market cap is less than US$100m (US$13.3m market cap). Anuncio • Dec 13
Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $3 million. Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $3 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Anuncio • Dec 03
Vicarious Surgical Inc. Announces Board and Committee Changes On December 1, 2025, Beverly Huss and Randy Clark each resigned as a member of the Board of Directors of Vicarious Surgical Inc., effective as of the Effective Date. Ms. Huss's and Mr. Clark's resignations were tendered in connection with a decision by the Board to reduce its size, and did not result from any disagreement regarding the Company's operations, policies or practices. In connection with Ms. Huss's and Mr. Clark's resignations, the Board reduced its size from nine members to seven as of the Effective Date. To address the resulting committee vacancies, Joseph Doherty was appointed as a member of the Audit Committee of the Board, Fuad Ahmad was appointed as a member of the Compensation Committee of the Board (the Compensation Committee"), and Victoria Carr-Brendel was appointed as Chair of the Compensation Committee, in each case effective as of the Effective Date. New Risk • Nov 20
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 0.9% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$53m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$19.4m market cap). Price Target Changed • Nov 13
Price target decreased by 16% to US$9.00 Down from US$10.75, the current price target is an average from 2 analysts. New target price is 159% above last closing price of US$3.48. Stock is down 67% over the past year. The company is forecast to post a net loss per share of US$7.99 next year compared to a net loss per share of US$10.74 last year. Anuncio • Oct 31
Vicarious Surgical Inc. to Report Q3, 2025 Results on Nov 13, 2025 Vicarious Surgical Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025 New Risk • Oct 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Market cap is less than US$100m (US$39.2m market cap). Anuncio • Oct 08
Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $5.864944 million. Vicarious Surgical Inc. has filed a Follow-on Equity Offering in the amount of $5.864944 million.
Security Name: Class A Common stock
Security Type: Common Stock
Securities Offered: 588,300
Price\Range: $5.1
Discount Per Security: $0.306
Security Name: Pre-funded warrants
Security Type: Equity Warrant
Securities Offered: 561,700
Price\Range: $5.0999
Discount Per Security: $0.306
Transaction Features: Registered Direct Offering Anuncio • Sep 26
Vicarious Surgical Inc. Announces Appointment of Joseph Doherty as Chairman of the Board Vicarious Surgical Inc. announced the appointment of Joseph Doherty as Chairman of the Company’s Board of Directors . Mr. Doherty has served as a member of the Board since June 2025. Since January 2025, Mr. Doherty has served as CEO of the Worcester City Campus Corporation, a not-for-profit corporation whose base corporate purpose is to foster, promote and support the University of Massachusetts. Mr. Doherty has held a range of senior leadership positions across the healthcare and medical device industries. He served as President of Scapa Healthcare and sat on the Board of Directors of Scapa Group, a publicly traded company on the AIM Stock Exchange. He was also President of Olympus Surgical Technologies America, a subsidiary of Olympus Corporation of the Americas. Earlier in his career, he spent 24 years at Johnson & Johnson in roles of increasing responsibility, ultimately serving as Vice President of Integration and Transformation. In addition to his executive experience, Mr. Doherty has served on the boards of the Massachusetts Biomedical Initiative, Immertec, and ZATA Pharmaceuticals, and as an advisor to AccuTec and Boardwalk Robotics. He earned a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College. Anuncio • Sep 17
Vicarious Surgical Inc. Announces Board Changes On September 12, 2025, Donald Tang resigned as a member of the Board of Directors of Vicarious Surgical Inc. effective as of September 12, 2025. Mr. Tang’s resignation did not result from any disagreement regarding the Company’s operations, policies or practices. In connection with Mr. Tang’s resignation, the Board appointed Victoria Carr-Brendel as a member of the Audit Committee of the Board. New Risk • Aug 28
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$49k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Earnings are forecast to decline by an average of 4.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Share price has been volatile over the past 3 months (16% average weekly change). Significant insider selling over the past 3 months (US$49k sold). Market cap is less than US$100m (US$39.1m market cap). New Risk • Aug 13
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$47m free cash flow). Earnings are forecast to decline by an average of 2.7% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$65m net loss in 2 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$61.4m market cap). Anuncio • Jul 30
Vicarious Surgical Inc. to Report Q2, 2025 Results on Aug 12, 2025 Vicarious Surgical Inc. announced that they will report Q2, 2025 results After-Market on Aug 12, 2025 Anuncio • Jul 13
The New York Stock Exchange Accepts Compliance Plan from Vicarious Surgical and to Quarterly Review to Confirm Compliance As previously reported, on April 10, 2025, Vicarious Surgical Inc. (the ‘Company’) received a written notice (the ‘Notice’) from the New York Stock Exchange (the ‘NYSE’) indicating the Company was no longer in compliance with the NYSE’s continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual (the ‘Minimum Market Capitalization Standard’) due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. In accordance with applicable NYSE procedures, the Company timely submitted a plan (the ‘Compliance Plan’) to the NYSE advising it of the definitive actions the Company has taken, is taking, and plans to take that would bring it into conformity with the Minimum Market Capitalization Standard within 18 months of receipt of the Notice (the ‘Cure Period’). On July 8, 2025, the NYSE notified the Company that it had accepted the Compliance Plan (the ‘Acceptance Letter’). The NYSE will review the Company on a quarterly basis to confirm compliance with the Compliance Plan. If the Company fails to comply with the Compliance Plan or does not meet the Minimum Market Capitalization Standard at the end of the Cure Period, it will be subject to NYSE’s prompt initiation of suspension and delisting procedures. The Acceptance Letter has no immediate impact on the listing of the Company’s Class A common stock, which will continue to be listed and traded on the NYSE during the Cure Period, subject to the Company’s continued compliance with the Compliance Plan and NYSE’s other continued listing standards. However, the Class A common stock trading symbol will have an added designation of ‘.BC’ to indicate that the status of the Class A common stock is below criteria with the NYSE continued listing standards. The ‘.BC’ indicator will be removed at such time as the Company regains compliance. The current noncompliance with the NYSE listing standards does not affect the Company’s ongoing business operations or its U.S. Securities and Exchange Commission (the ‘Commission’) reporting requirements. The Company is considering all available options to regain compliance with NYSE’s continued listing standards. Board Change • Jul 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Fuad Ahmad was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Anuncio • Jun 30
Vicarious Surgical Inc. Announces Changes to Its Board Vicarious Surgical Inc. announced the election of Fuad Ahmad and Joseph Doherty to the Board of Directors at the Company’s 2025 Annual Meeting of Stockholders held on June 27, 2025. The Company also announced the departure of Ric Fulop from the Board of Directors effective as of the Annual Meeting. Mr. Ahmad has been a partner at FLG Partners, a CEO and CFO consulting practice and board advisory services firm, since 2013. From November 2020 to March 2025, he served as CFO of Iridex Corporation, a medical device company. Prior to that, Mr. Ahmad served as CFO at each of Mitek Systems, Vaxart Inc., Cutera Inc., and Telenav Inc. Prior to joining FLG Partners, he served as CFO of Sezmi Corporation, a Morgenthaler Ventures-backed cloud-based software platform. Prior to his service with Sezmi Corporation, Mr. Ahmad served as Senior Vice President and CFO of Globalstar Inc., a public company that builds and operates low-earth orbit satellite-based digital telecommunications systems. Mr. Ahmad graduated from Brigham Young University with a Bachelor of Science in Finance. Mr. Doherty has served as CEO of the Worcester City Campus Corporation since January 2025. Since 2020, Mr. Doherty has served as a teacher at Saint John’s High School, and since March 2022, he has also served as a member of the board of directors of Immertec. From 2021 to 2025, he served as the Director for the BOLT initiative at the Massachusetts Biomedical Initiative. From January 2019 to August 2020, he served as the President of Scapa Healthcare, and from January 2019 to May 2020, he was a member of the board of directors of Scapa Group. From 2015 to 2019, Mr. Doherty served in roles of increasing responsibility, including as President of Olympus Surgical Technologies America. He also spent over 24 years with Johnson & Johnson and held various roles with increasing responsibilities, ultimately serving as the Vice President of Integration and Transformation. Mr. Doherty received a Bachelor of Science in Engineering from the United States Military Academy at West Point and a Master of Business Administration from Nichols College. Anuncio • Apr 30
Vicarious Surgical Inc., Annual General Meeting, Jun 27, 2025 Vicarious Surgical Inc., Annual General Meeting, Jun 27, 2025. New Risk • Apr 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (US$50.2m market cap). Anuncio • Apr 29
Vicarious Surgical Inc. to Report Q1, 2025 Results on May 12, 2025 Vicarious Surgical Inc. announced that they will report Q1, 2025 results After-Market on May 12, 2025 New Risk • Apr 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$50m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Market cap is less than US$100m (US$39.4m market cap). Anuncio • Apr 12
Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") announced that on April 10, 2025, the Company received written notice (the "Notice") from the New York Stock Exchange (the "NYSE") indicating that the Company is no longer in compliance with the continued listing standards set under Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, the Company's last reported stockholders' equity was less than $50 million. As set in the Notice, as of April 9, 2025, the 30 trading-day average market capitalization was approximately $47.4 million, and the Company's last reported stockholders' equity as of December 31, 2024 was less than $50 million. This notice does not impact the Company's business operations. In accordance with applicable NYSE procedures, the Company has 45 days from the date the Notice was received to submit a plan advising the NYSE of the definitive action(s) the Company has taken, is taking, or plans to take to bring it into compliance with Section 802.01B within 18 months of receipt of the Notice. If the Company's plan is not submitted on a timely basis or is not accepted, the NYSE will initiate delisting proceedings. Pending NYSE acceptance of the plan, the Company's Class A common stock will continue to be listed and traded on the NYSE during the 18-month cure period. Continued listing is also subject to the Company's compliance with other applicable NYSE requirements and to quarterly NYSE review of the Company's progress toward achieving compliance with the plan. In the interim, the Company's Class A common stock will continue to trade on the NYSE under the symbol "RBOT" with the designation of ".BC" to indicate the status of the shares as "below criteria," but is otherwise not immediately impacted by the Notice. The ".BC" indicator will be removed at such time as the Company regains compliance. The Notice also does not affect Securities and Exchange Commission reporting obligations by the Company. The Company is considering all available options to regain compliance with the NYSE's continued listing standards. Anuncio • Mar 25
Vicarious Surgical Inc. Announces Transition of Company President, Randy Clark to Board Member, Effective April 25, 2025 Vicarious Surgical Inc. announced that Company President, Randy Clark, will transition to Board Member, effective April 25, 2025, pending customary conflict checks. As President, Mr. Clark directed critical business functions, including product development, operations, clinical regulatory, quality affairs, and human resources. He spearheaded the strategic development of Vicarious Surgical’s manufacturing capabilities, establishing key partnerships and strengthening the supply chain. Notably, he implemented key personnel realignment, streamlined business processes, and formalized workflows and standardized procedures in order to position the Company for its next phase of growth. New Risk • Mar 18
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$51m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$51m free cash flow). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$56m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$56.9m market cap). Anuncio • Mar 13
Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer, Effective from April 1, 2025 Vicarious Surgical announced the appointment of Sarah Romano as Chief Financial Officer, Effective date is April 1, 2025. Ms. Romano will oversee Vicarious Surgical’s financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the healthcare sector, through successful fundraising and M&A initiatives. Most recently, Ms. Romano served as Chief Financial Officer of Entero Therapeutics, where she oversaw financial strategy, operations, and compliance, raising significant funding and successfully executing product in-licensing partnerships. Previously, as Chief Financial Officer of Kiora Pharmaceuticals, Ms. Romano secured over $50 million in funding and spearheaded M&A activities, overseeing due diligence and integration. Earlier in her career, Ms. Romano progressed through roles of increasing responsibility, including corporate controller, with responsibilities encompassing budget reviews, financial forecasting and analysis, internal controls oversight, and SEC reporting. Ms. Romano holds a Master of Accountancy from Boston College and a B.A. in Accounting from the College of the Holy Cross. Anuncio • Mar 04
Vicarious Surgical Inc. to Report Q4, 2024 Results on Mar 17, 2025 Vicarious Surgical Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 17, 2025 Anuncio • Feb 19
Vicarious Surgical Inc. Announces Chief Operating Officer Changes, Effective April 1, 2025 Vicarious Surgical Inc. announced Chief Operating Officer (COO) John Mazzola will retire, effective April 1, 2025, after nearly 40 years in healthcare manufacturing, supply chain and quality control. Mr. Mazzola will continue to serve as COO until the effective date, at which time his responsibilities will transition to Randy Clark, Company President. Anuncio • Dec 08
Vicarious Surgical Inc. Announces Departure of William Kelly as Chief Financial Officer, Effective January 2, 2025 Vicarious Surgical Inc. announced the pending departure of William Kelly, its Chief Financial Officer (CFO), to pursue other career opportunities, after nearly four years of dedicated service with the Company. Mr. Kelly has served as Vicarious Surgical’s CFO since January 2021. He will assist the Company to ensure minimal disruption and a successful transition of responsibilities prior to his departure, which is slated for January 2, 2025. The Company has initiated a CFO succession process and will provide updates as appropriate. Price Target Changed • Nov 15
Price target increased by 18% to US$11.17 Up from US$9.50, the current price target is an average from 3 analysts. New target price is 19% above last closing price of US$9.36. Stock is up 0.6% over the past year. The company is forecast to post a net loss per share of US$11.04 next year compared to a net loss per share of US$14.60 last year. New Risk • Nov 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$70m net loss in 3 years). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (US$49.5m market cap). Anuncio • Oct 29
Vicarious Surgical Inc. to Report Q3, 2024 Results on Nov 12, 2024 Vicarious Surgical Inc. announced that they will report Q3, 2024 results After-Market on Nov 12, 2024 Anuncio • Jul 30
Vicarious Surgical Inc. to Report Q2, 2024 Results on Aug 12, 2024 Vicarious Surgical Inc. announced that they will report Q2, 2024 results After-Market on Aug 12, 2024 Price Target Changed • Jul 16
Price target increased by 21% to US$37.50 Up from US$31.00, the current price target is an average from 2 analysts. New target price is 340% above last closing price of US$8.53. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$11.28 next year compared to a net loss per share of US$14.60 last year. Anuncio • Apr 24
Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024 Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024, at 14:00 US Eastern Standard Time. Agenda: To elect seven directors to serve one-year terms expiring in 2025; to approve an amendment to the Vicarious Surgical Inc. 2021 Equity Incentive Plan (the Plan) to increase the number of shares of common stock authorized for issuance under the Plan by 5,000,000 shares; to approve an amendment to the Companys Certificate of Incorporation, as amended (the Certificate of Incorporation), to effect a reverse stock split. Anuncio • Apr 09
Vicarious Surgical Inc. to Report Q1, 2024 Results on Apr 29, 2024 Vicarious Surgical Inc. announced that they will report Q1, 2024 results After-Market on Apr 29, 2024 New Risk • Mar 05
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings are forecast to decline by an average of 0.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$82m net loss in 3 years). Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (US$63.3m market cap). Anuncio • Feb 13
Vicarious Surgical Inc. to Report Q4, 2023 Results on Mar 04, 2024 Vicarious Surgical Inc. announced that they will report Q4, 2023 results After-Market on Mar 04, 2024 Anuncio • Jan 30
Vicarious Surgical Inc. Announces Management Changes Vicarious Surgical Inc. announced that Randy Clark has been appointed President effective, January 29, 2024. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will assume responsibility for the day-to-day oversight of many core business functions including product development, operations, commercial strategy, clinical, regulatory and quality affairs, and human resources. Mr. Clark joins as an accomplished leader with more than 20 years of medical device industry experience and has been instrumental in the development, manufacture, and commercialization of several innovative medical device solutions throughout his career. Most recently, Mr. Clark served as the Global President of the Health Solutions Business Unit at Flex Ltd., a prominent global supply chain, manufacturing, and design solutions provider. Prior to this, he spent 15 years at Olympus Corporation of the Americas, where he held various roles with increasing responsibilities, ultimately serving as President and a member of their board of directors, overseeing full P&L management for the Americas. Mr. Clark earned a Bachelor of Science in Business Administration from Drake University, a Master of Business Administration degree from Colorado State University, and completed the Advanced Management program at Harvard Business School. In connection with the appointment of Mr. Clark, Adam Sachs stepped down from his role as President. Mr. Sachs will continue to serve as the Chief Executive Officer of the Company. Price Target Changed • Nov 17
Price target decreased by 84% to US$1.13 Down from US$7.00, the current price target is an average from 3 analysts. New target price is 319% above last closing price of US$0.27. Stock is down 92% over the past year. The company is forecast to post a net loss per share of US$0.56 compared to earnings per share of US$0.042 last year. Anuncio • Oct 27
Vicarious Surgical Inc. to Report Q3, 2023 Results on Nov 13, 2023 Vicarious Surgical Inc. announced that they will report Q3, 2023 results After-Market on Nov 13, 2023 New Risk • Oct 03
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$89.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Shareholders have been diluted in the past year (41% increase in shares outstanding). Significant insider selling over the past 3 months (US$99k sold). Market cap is less than US$100m (US$89.6m market cap). Anuncio • Sep 24
Vicarious Surgical Receives Continued Listing Standard Notice From NYSE Vicarious Surgical Inc. announced that on September 20, 2023, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE. The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to cure the stock price deficiency and to return to compliance with the NYSE continued listing standard. Pursuant to the NYSE’s rules, the Company has a six-month period following receipt of the Notice to regain compliance with the NYSE’s minimum share price requirement. The Company can regain compliance with the minimum share price requirement at any time during the cure period if, on the last trading day of any calendar month during the cure period, or on the last day of the cure period, the Company’s Class A common stock has (i) a closing share price of at least $1.00, and (ii) an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month or on the last day of the cure period, as applicable. The Company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to Board and stockholder approval at the Company’s next annual meeting, to regain compliance. The Company’s Class A common stock will continue to be listed and traded on the NYSE during this period, subject to its compliance with other NYSE continued listing standards. The receipt of the Notice does not affect the Company’s business, operations or reporting requirements with the Securities and Exchange Commission. New Risk • Aug 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$50m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (42% increase in shares outstanding). Significant insider selling over the past 3 months (US$147k sold). Anuncio • Jul 14
Vicarious Surgical Inc. to Report Q2, 2023 Results on Jul 27, 2023 Vicarious Surgical Inc. announced that they will report Q2, 2023 results After-Market on Jul 27, 2023 New Risk • Jun 29
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$147k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$62m net loss in 3 years). Shareholders have been diluted in the past year (4.7% increase in shares outstanding). Significant insider selling over the past 3 months (US$147k sold). Recent Insider Transactions • May 27
Co-Founder recently sold US$54k worth of stock On the 22nd of May, Adam Sachs sold around 24k shares on-market at roughly US$2.24 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$325k. Recent Insider Transactions Derivative • May 26
Co-Founder notifies of intention to sell stock Adam Sachs intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of May. If the sale is conducted around the recent share price of US$2.07, it would amount to US$50k. For the year to December 2020, Adam's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2022, Adam's direct individual holding has increased from 11.30m shares to 11.39m. Company insiders have collectively bought US$245k more than they sold, via options and on-market transactions, in the last 12 months. Anuncio • May 19
Vicarious Surgical Inc. Announces Promotion of John Mazzola to Chief Operating Officer Vicarious Surgical Inc. announced the promotion of John Mazzola to Chief Operating Officer. John joined Vicarious Surgical in March of 2022 as SVP of Operations and has over 35 years of medical device industry experience. He has been involved with over 25 medical device product launches encompassing both Class II and Class III devices. Prior to joining the Vicarious Surgical team, he spent 13 years in senior executive roles and product development leadership positions, including serving as VP of Operations at Becton Dickinson Surgery overseeing a network of 10 manufacturing sites, a business planning and procurement organization, an advanced manufacturing engineering team, and the business’ environmental health and safety responsibilities. In the past year, John has led strategic manufacturing plans for the Vicarious Surgical robotic system, overseeing operations and quality organizations. In the newly created Chief Operating Officer role, John’s oversight expands to include the Product Development, Clinical & Regulatory Affairs, IT and People & Culture functions of the business for enhanced workflow efficiency and a continued focus on manufacturing and procurement optimization. Recent Insider Transactions • Mar 31
Insider recently bought US$153k worth of stock On the 27th of March, Philip Liang bought around 74k shares on-market at roughly US$2.07 per share. This transaction amounted to 3.6% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Insiders have collectively bought US$220k more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Mar 25
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to US$1.90, the stock trades at a trailing P/E ratio of 46.4x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 57% over the past year. Recent Insider Transactions • Mar 17
Insider recently bought US$139k worth of stock On the 13th of March, Philip Liang bought around 59k shares on-market at roughly US$2.36 per share. This transaction amounted to 3.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Despite this recent purchase, insiders have collectively sold US$134k more in shares than they bought in the last 12 months. Recent Insider Transactions • Mar 10
Insider recently bought US$78k worth of stock On the 2nd of March, Philip Liang bought around 30k shares on-market at roughly US$2.60 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth US$241k. Despite this recent purchase, insiders have collectively sold US$366k more in shares than they bought in the last 12 months. Recent Insider Transactions • Feb 27
Co-Founder recently sold US$65k worth of stock On the 21st of February, Adam Sachs sold around 24k shares on-market at roughly US$2.78 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$260k. Recent Insider Transactions Derivative • Feb 26
Co-Founder notifies of intention to sell stock Adam Sachs intends to sell 24k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of February. If the sale is conducted around the recent share price of US$3.06, it would amount to US$72k. For the year to December 2020, Adam's total compensation was 5% salary and 95% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Adam's direct individual holding has increased from 11.33m shares to 11.34m. Company insiders have collectively sold US$906k more than they bought, via options and on-market transactions in the last 12 months. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$2.75, the stock trades at a trailing P/E ratio of 67.2x. Average forward P/E is 32x in the Medical Equipment industry in the US. Total loss to shareholders of 51% over the past year. Price Target Changed • Feb 16
Price target decreased by 21% to US$7.75 Down from US$9.75, the current price target is an average from 4 analysts. New target price is 139% above last closing price of US$3.24. Stock is down 47% over the past year. The company is forecast to post a net loss per share of US$0.59 compared to earnings per share of US$0.042 last year. Recent Insider Transactions • Feb 14
Insider recently bought US$241k worth of stock On the 8th of February, Philip Liang bought around 79k shares on-market at roughly US$3.05 per share. This transaction amounted to 4.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$670k more in shares than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$3.14, the stock trades at a trailing P/E ratio of 10.1x. Average forward P/E is 33x in the Medical Equipment industry in the US. Total loss to shareholders of 49% over the past year. Anuncio • Jan 31
Vicarious Surgical Inc. to Report Q4, 2022 Results on Feb 13, 2023 Vicarious Surgical Inc. announced that they will report Q4, 2022 results After-Market on Feb 13, 2023 Anuncio • Jan 24
Vicarious Surgical Inc. Announces Changes to Board of Directors Vicarious Surgical Inc. announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today. Dr. Carr-Brendel possesses twenty-four years of medical device development experience leading R&D, new product development, divisional, and business development functions. She currently serves as the Group Vice President of Cochlear Implants at Sonova Group/President of Advanced Bionics, a Sonova company and a global leader in the treatment of severe-to-profound hearing loss. Prior to this, Dr. Carr-Brendel served as the Chief Executive Officer for JenaValve, a private company focused on developing transcatheter aortic valve repair systems to treat patients suffering from aortic valve disease. Between 2004 and 2015, she served in roles of increasing responsibility at Boston Scientific, eventually overseeing the acquisition of Bayer’s Interventional radiology division in 2014. Dr. Carr-Brendel received a Bachelor’s degree in Biology from Monmouth College, a Master of Science in Microbiology from Iowa State University, and a Ph.D. in Microbiology and Immunology from the University of Illinois at Chicago. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment improved over the past week After last week's 22% share price gain to US$2.33, the stock trades at a trailing P/E ratio of 7.5x. Average forward P/E is 32x in the Medical Equipment industry in the US. Total loss to shareholders of 70% over the past year. Anuncio • Dec 23
Vicarious Surgical Completes Public Demonstration of Beta 2 Surgical Robotic System Vicarious Surgical Inc. hosted the first public demonstration of its Beta 2 surgical robotic platform on December 6, 2022, highlighting the latest evolution of its differentiated technology and showcasing recent cadaveric testing. Supporting presentations by representatives from leading healthcare provider University Hospitals and renowned surgeon Dr. Igor Belyansky outlined the extensive opportunity for Vicarious to address current shortcomings in surgical robotics at the system and user level. As part of the Beta 2 Demonstration Day event, Dr. Belyansky reviewed intra-operative video of his recent cadaveric ventral hernia repair procedures in which he utilized the Vicarious Surgical Beta 2 system. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment deteriorated over the past week After last week's 25% share price decline to US$1.87, the stock trades at a trailing P/E ratio of 6x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 82% over the past year. Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$2.82, the stock trades at a trailing P/E ratio of 9.1x. Average forward P/E is 31x in the Medical Equipment industry in the US. Total loss to shareholders of 74% over the past year. Recent Insider Transactions • Nov 25
Co-Founder recently sold US$74k worth of stock On the 21st of November, Adam Sachs sold around 23k shares on-market at roughly US$3.25 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Adam has been a net seller over the last 12 months, reducing personal holdings by US$187k. Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Independent Director Phil Liang is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment improved over the past week After last week's 17% share price gain to US$3.73, the stock trades at a trailing P/E ratio of 25.7x. Average forward P/E is 28x in the Medical Equipment industry in the US. Total loss to shareholders of 71% over the past year. Anuncio • Oct 25
Vicarious Surgical Inc. to Report Q3, 2022 Results on Nov 07, 2022 Vicarious Surgical Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022 Recent Insider Transactions Derivative • Oct 22
CFO & Treasurer notifies of intention to sell stock William Kelly intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 18th of October. If the sale is conducted around the recent share price of US$3.65, it would amount to US$56k. Since December 2021, William's direct individual holding has increased from 2.07k shares to 15.52k. Company insiders have collectively sold US$1.3m more than they bought, via options and on-market transactions in the last 12 months. Anuncio • Oct 21
Vicarious Surgical Inc. Announces Changes to Board of Directors Vicarious Surgical Inc. announced the resignation of technology-focused venture capitalists Dror Berman and Samir Kaul from the Vicarious Surgical Board of Directors effective October 18, 2022. The Company also announced the appointment of Beverly Huss to the Vicarious Surgical Board of Directors, effective as of the same day. Ms. Huss will serve as a member of the Board’s Audit Committee. Ms. Huss co-founded and previously served as Chief Executive Officer of Pagonia Medical, a development stage company in the tissue preservation market, where she led the incorporation efforts and seed capital financing. Prior to this, Ms. Huss served over several years as Chief Executive Officer of Qool Therapeutics Inc., a therapeutic hypothermia and medical device company, and as Chief Executive Officer of Vibrynt Inc., a start-up medical device company dedicated to creating minimally invasive therapies for patients suffering from morbid obesity. From 1986 to 2005, Ms. Huss served in various general management roles of increasing responsibility within the research and development, regulatory affairs, marketing and sales departments of Guidant Corporation, a market leading medical device company focused on treatment of cardiac rhythm management, cardiovascular and peripheral vascular disease through minimally invasive therapies, until its acquisition by Boston Scientific Corporation. Ms. Huss is a veteran board member with nearly two decades of board experience and presently resides on the Boards of Accuray Incorporated, Ancora Heart Inc., Iridex Corporation and Madorra Inc. She received a Bachelor of Science in metallurgical engineering from the University of Illinois Urbana-Champaign and a Master’s degree in technology management from Pepperdine University. 
